DURECT

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DURECT reports robust revenue growth and advances AHFIRM trial

DURECT's financials improved notably in 2022, driven by milestone payments and revenue growth.
AHFIRM trial progress and potential of larsucosterol offer promising prospects for the company.
Balancing high R&D costs, regulatory milestones, and market competition are key challenges.
Strategic management of cash reserves and successful trial outcomes are critical for future success.

DURECT (DRRX) advances promising AH treatment with strong Q1 results

DURECT's Q1 performance reflects progress in the development of Larsucosterol for AH.
Strengths lie in positive clinical data, regulatory support, and market awareness.
Challenges include market recall, pricing strategy, and potential dosing issues.
Opportunities exist in market expansion, regulatory milestones, and cost-saving potential.

DURECT reports Q2 revenue, progresses AHFIRM trial, eyes oncology expansion

DURECT's Q2 2023 performance reflects a balance between revenue generation, strategic investments, and financial strengthening.
The company's strengths lie in advancing clinical trials, exploring new markets, and planning for commercial success.
Challenges include regulatory hurdles, financial sustainability, and addressing analyst inquiries, while opportunities abound in oncology expansion and market growth.
Overall, DURECT's focus on innovation, strategic partnerships, and market awareness positions it for future success and growth.

DURECT reports positive trial results for larsucosterol in AH

DURECT's financials and cash position remain stable, with a successful net proceeds raise and operational funding secured.
Larsucosterol's positive trial results and FDA Fast Track designation position it as a promising treatment for AH.
While challenges exist in regulatory pathways and trial complexities, the market potential for larsucosterol is substantial.
Overall, DURECT's focus on addressing AH with an effective treatment underscores its commitment to patient care.

DURECT reports revenue decline but positive trial results for larsucosterol

DURECT saw a decline in revenues but managed to reduce R&D and SG&A expenses in 2023.
Positive trial results and feedback position larsucosterol as a promising therapy for alcohol-associated hepatitis.
Navigating revenue challenges, regulatory discussions, and cost management are key focus areas for DURECT.

DURECT reports Q1 revenue dip, eyes FDA approval for AH treatment

DURECT's Q1 2024 performance saw revenue decline but cost management improvements.
Progress in larsucosterol Phase III trial and AHFIRM data acceptance signal positive developments.
While revenue challenges persist, opportunities in AH treatment market and financial stability are notable.
Strategic focus on AH patients' needs and efficient trial design position DURECT for future success.

DURECT reports revenue growth and progress in life-saving therapy trials

DURECT's Q2 2024 performance showed revenue growth and significant expense reductions.
Strengths lie in breakthrough therapy designation, positive study results, and cost-efficient trial planning.
Challenges include managing cash burn, meeting trial timelines, and industry competition.
Opportunities exist in market expansion, partnerships, pipeline diversification, and cost optimization.

DURECT reports improved Q3 financials and progresses key clinical trials

DURECT's financials improved in Q3 2024 with lower expenses and stable revenues, while advancing key clinical trials.
Despite challenges like licensing agreement termination, the company is poised for growth with promising trial results and strategic opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-  Webcast of Earnings Call Today, March 7 th at 4:30 p.m. ET -  Topline data from AHFIRM trial expected in 2023 CUPERTINO, Calif.

DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update

CUPERTINO, Calif. , Feb. 28, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023.

DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7

CUPERTINO, Calif. , Feb. 3, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into a definitive agreement with a leading institutional healthcare investor and an existing institutional investor for the purchase and sale of an aggregate of 1,700,000 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase 300,000 shares of common stock, and accompanying warrants to purchase up to 2,000,000 shares of common stock in a registered direct offering (the "Offering").

DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants

Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?

CUPERTINO, Calif. , Nov. 28, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, announced that DURECT's board of directors today determined that the Company will effect a reverse stock split at a ratio of 1-for-10 as of 5:01 p.m.

DURECT Announces 1-for-10 Reverse Stock Split

DURECT Corporation (NASDAQ:DRRX ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Norman Sussman - Chief Medical Officer Keith Louie - Business Development and Commercialization Conference Call Participants Kristen Kluska - Cantor Fitzgerald Operator Greetings. And welcome to the DURECT Corporation Third Quarter 2022 Earnings Conference Call.

DURECT Corporation (DRRX) Q3 2022 Earnings Call Transcript

-  Webcast of Earnings Call Today, November 2 nd at 4:30 p.m. ET -  AHFIRM trial timeline continues to improve CUPERTINO, Calif.

DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs

CUPERTINO, Calif. , Oct. 26, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022.

DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2

AHFIRM enrollment surpasses 200 of the planned 300 AH patients Enrollment completion now anticipated in Q2 2023 CUPERTINO, Calif. , Oct. 6, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, today announced the enrollment of more than 200 of the planned 300 patients in its Phase 2b AHFIRM trial.

DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial

POSIMIR® is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery DURECT recently received an $8 million milestone payment for a new patent issuance and has now earned a $2 million milestone payment for first commercial sale of POSIMIR ATHLONE, Ireland and CUPERTINO, Calif. , Sept. 26, 2022 /PRNewswire/ -- Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology  company and portfolio business of Gurnet Point Capital, and DURECT Corporation (Nasdaq: DRRX) today announced the recent commercial launch of POSIMIR® (bupivacaine solution) in the United States.

Innocoll and DURECT Announce U.S. launch of POSIMIR®

DURECT Corporation (NASDAQ:DRRX ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Norman Sussman - Chief Medical Officer Conference Call Participants Rick Miller - Cantor Fitzgerald Thomas Yip - H.C. Wainwright Operator Greetings.

DURECT Corporation's (DRRX) CEO Jim Brown on Q2 2022 Results - Earnings Call Transcript

-  Webcast of Earnings Call Today, August 4 th at 4:30 p.m. ET -  Enrollment accelerating in the AHFIRM trial CUPERTINO, Calif.

DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs

CUPERTINO, Calif. , July 27, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Thursday, August 4, 2022.

DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4

Applied Genetic Technologies

Alzamend Neuro

Ampio Pharmaceuticals Inc

Bird Rides

Curis

Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance. The post 6 Penny Stocks With 1,000% Upside Potential appeared first on InvestorPlace.

6 Penny Stocks With 1,000% Upside Potential

CUPERTINO, Calif. , July 5, 2022 /PRNewswire/ --  DURECT Corporation  (Nasdaq: DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M.

DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

DURECT Corp, Inc. (NASDAQ:DRRX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Matthew Hogan - IR James Brown - Co-Founder, CEO, President & Director Norman Sussman - Chief Medical Officer Conference Call Participants François Brisebois - Oppenheimer Thomas Yip - HC Wainwright Geoffrey de Sibert - KB Advisors Matthew Hogan Good afternoon, and welcome to our First Quarter 2022 Earnings Conference Call. This is Matt Hogan, from DURECT Corporation.

DURECT Corp (DRRX) CEO James Brown on Q1 2022 Results - Earnings Call Transcript

Durect (DRRX) delivered earnings and revenue surprises of 0% and 21.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates

- Webcast of Earnings Call Today, May 4 th at 4:30 p.m. ET - Adding new clinical sites and patient dosing progressing in the AHFIRM trial CUPERTINO, Calif.

DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs

CUPERTINO, Calif. , April 27, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Wednesday, May 4, 2022.

DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4

CUPERTINO, Calif., March 23, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit

CUPERTINO, Calif., March 9, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference

DURECT Corporation's (DRRX) CEO Jim Brown on Q4 2021 Results - Earnings Call Transcript

CUPERTINO, Calif., March 7, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2021 and provided a corporate update.

DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs

CUPERTINO, Calif., March 1, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (AH) patients.

DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis

CUPERTINO, Calif., Feb. 28, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2021 financial results and host a conference call after the market close on Monday, March 7, 2022.

News for DURECT Stock (DRRX)